Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound serving as protein degradation agent and preparation method and application thereof

A compound, alkyl technology, applied to the compound as a protein degrading agent and its preparation and application fields, can solve problems such as not necessarily applicable

Active Publication Date: 2021-02-23
SHANGHAI JEMINCARE PHARMA CO LTD +1
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This also means that common drug-chemical transformation strategies (such as equivalent replacement of effective fragments, etc.) are not necessarily applicable in the design of such molecules

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound serving as protein degradation agent and preparation method and application thereof
  • Compound serving as protein degradation agent and preparation method and application thereof
  • Compound serving as protein degradation agent and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

reference example 1

[0154] Reference Example 1: Preparation of Intermediate I-1

[0155]

[0156] 5-Bromo-3,3-dimethyl-1H-indol-2-one (3.50 g, 14.60 mmol) and potassium tert-butoxide (2.46 g, 21.90 mmol) were dissolved in dimethylsulfoxide ( 50mL). After the mixture was stirred and reacted for 30 minutes, 2-chloro-4-fluorobenzonitrile (2.72 g, 17.50 mmol) was added to the above reaction solution, and the reaction solution was stirred at 20° C. for 20 hours. Water (100 mL) and ethyl acetate (50 mL) were added to the reaction system, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-1.

[0157] LC-MS(ESI)[M+H] + 375.1;

[0158] 1 H NMR (400MHz, DMSO-d 6 )δ8.18(d, J=8.4Hz, 1H), 7.96(d, J...

reference example 2

[0159] Reference Example 2: Preparation of Intermediate I-2

[0160]

[0161] At room temperature, intermediate I-1 (1.00g, 2.67mmol), pinacol diboronate (1.02g, 4.01mmol), [1,1'-bis(diphenylphosphino)ferrocene] Palladium dichloride (195mg, 0.27mmol) and potassium acetate (785mg, 8.01mmol) were dissolved in dioxane (40mL), and the reaction solution was replaced with nitrogen three times, then heated to 90°C and stirred for two hours. The reaction solution was evaporated to dryness under reduced pressure, and the residue was separated and purified by silica gel chromatography to obtain intermediate I-2.

[0162] LC-MS(ESI)[M+H] + 423.3

reference example 3

[0163] Reference Example 3: Preparation of Intermediate I-3

[0164]

[0165] At room temperature, intermediate I-2 (100mg, 0.24mmol), 2-fluoro-4-bromophenol (50mg, 0.26mmol), [1,1'-bis(diphenylphosphino)ferrocene] Palladium dichloride (17mg, 0.024mmol) and potassium carbonate (100mg, 0.72mmol) were dissolved in dioxane and water (10mL / 3mL), and the reaction solution was replaced with nitrogen three times, then heated to 80°C and stirred for two hours. The reaction solution was cooled to room temperature, water (15 mL) and ethyl acetate (15 mL) were added to the mixture, the organic phase was separated, and the aqueous phase was extracted with ethyl acetate (50 mL×2). The organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography to obtain intermediate I-3.

[0166] LC-MS(ESI)[M+H] + 407.1

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a compound serving as a protein degradation agent and a preparation method and application thereof, and particularly discloses a compound shown as a formula (I) and pharmacologically acceptable salt thereof and application of the compound serving as an androgen receptor (AR) for degradation.

Description

technical field [0001] The present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, and the application of the compound as an androgen receptor (AR) degradation agent. Background technique [0002] Prostate cancer (PCa) is one of the most common cancers, surpassing lung cancer as the most common male cancer in the United States. Prostate cancer has no obvious symptoms in the early stage, so when it is generally discovered, the patient will have symptoms such as frequent urination, dysuria, hematuria, and painful urination, and may spread to other parts. In 2016, the number of new prostate cancer patients in my country was 120,000, and it is estimated that this number will rise to 237,000 by 2030, with a compound annual growth rate of 5% for the number of new patients. It also means that in the next 10 years, the incidence of prostate cancer in my country will enter a peak period and become the number one killer of ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K5/062C07K5/02C07K5/097A61K38/05A61K38/06A61P35/00A61P25/00A61P21/00
CPCC07K5/06034C07K5/021C07K5/0821A61P21/00A61P25/00A61P35/00A61K38/00
Inventor 陆洪福邢唯强吕永聪雷煜肖志伟张志成彭建彪郭海兵
Owner SHANGHAI JEMINCARE PHARMA CO LTD